Watching Denali Therapeutics Inc.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsAcquisition/DispositionItem 2.01 · 8-KLOW RiskPositive
Denali Therapeutics Inc.
Filed: Jul 27, 2026CIK: 0001714899
AI Executive Summary
AI-powered analysis of 8-K filing content
Denali Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million on July 27, 2026, following FDA approval of AVLAYAH for Hunter syndrome. This strategic divestiture provides substantial capital for reinvestment in R&D initiatives.
Key Takeaways
Denali received $195.0 million in gross proceeds from the sale of its PRV to a large pharmaceutical company
The PRV was obtained following FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026
2 more takeaways
Filing Overview
Form Type8-K
Filing DateJul 27, 2026
Item2.01
CategoryAcquisition/Disposition
CIK0001714899
Accession #dnli-20260727
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
divestitureregulatory
What This Means
The company completed a major acquisition or sold off a significant asset. This reshapes the company's portfolio and strategic direction.